Please login to the form below

Not currently logged in

Crescendo Biologics appoints Dr Kevin Johnson as chairman

Brings Cambridge, UKfirm experience from Pangenetics

Crescendo Biologics Dr Kevin JohnsonCambridge, UK-based biopharmaceutical company Crescendo Biologics has appointed Dr Kevin Johnson as non-executive chairman of the board of directors.

Dr Johnson brings 27 years of antibody development experience to the role, most notably as ex-CTO of Cambridge Antibody Technology and ex-CEO of Pangenetics, which acquired by Abbott in 2009.

Since 2003 he has been on the life sciences team of Europe and San Francisco based global venture capital firm Index Ventures, focusing on drug development companies.

He said: “Crescendo Biologics has a very promising pipeline in development based on its unique Humabodies platform.

“The Company is at an exciting inflection point, expanding its oncology pipeline by targeting a range of cancer indications with its multi-specific checkpoint modulators and its Humabody Drug Conjugates.”

Crescendo's discovery programmes are focused on the development of innovative medicines for the treatment of cancer, including its proprietary Humabody Drug Conjugates (HDCs) and checkpoint modulators such as anti-PD-1 Humabodies

The company says its Humabodies have 'excellent potency and druggability including superior CMC properties for drug development'. 

Commenting on Dr Johnson's appointment, the firm's new CEO Dr Peter Pack said: “Kevin is a highly seasoned executive to head up our board of directors as we move the focus of the company into the field of oncology.

“His past experience is very relevant - from Cambridge Antibody Technologies where he was responsible for its antibody platform technologies to Pangenetics which specialised in taking antibodies from the late research stage through to clinical proof of concept. His input has already proved instrumental to the planning of our new strategy.”

18th November 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....
The Periodic Table of Healthcare Communications
The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing....